YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
argenx SE ARGX announced positive top-line data from a phase II study evaluating FB102, an investigational therapy in adults with celiac disease. Celiac disease is a chronic autoimmune condition triggered by gluten, a protein found in whea…
Editas Medicine EDIT announced that it has received approval to initiate the first-in-human phase I/II Strive clinical study of EDIT-401, its investigational in vivo gene-editing candidate for heterozygous familial hypercholesterolemia (He…
argenx ARGX suffered a clinical setback after deciding to discontinue the late-stage UNITY study evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate-to-severe Sjögren's disease. The…
Lipocine LPCN is an emerging specialty pharmaceutical company focused on developing oral therapies for diseases with significant unmet medical needs. The company offers a mix of an approved commercial product, a potentially differentiated…
Ultragenyx Pharmaceutical RARE has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. The transaction is expected to provide the rare-disease drugmaker with a meaningful inf…
Shares of Eton Pharmaceuticals ETON have gained about 108% over the past six months compared with the industry's 0.7% growth, fueled by growing investor confidence in the company's strong commercial execution, rapid revenue growth and an e…
Shares of Agios Pharmaceuticals AGIO have declined 29% over the past three months despite strong growth in mitapivat sales in the second quarter of 2026. The decline largely reflects setbacks to tebapivat, a key pipeline candidate, which h…
Pacira BioSciences PCRX announced an exclusive agreement with Molteni Farmaceutici to distribute and commercialize Exparel (bupivacaine liposome injectable suspension) in the EU and the United Kingdom. Molteni is an Italian specialty pharm…
Ultragenyx Pharmaceutical RARE announced that the European Medicines Agency (EMA) has validated its Marketing Authorization Application (MAA) for the investigational gene therapy rebisufligene etisparvovec (also known as UX111) to treat mu…
Novo's NVO denecimig biologics license application (BLA) review in the United States is facing an extended timeline after the FDA informed the company that the review of the investigational therapy for haemophilia A remains ongoing. The FD…
Novo's NVO oral Wegovy (semaglutide) is showing real-world weight-loss benefits among adults with overweight or obesity who switched from injectable GLP-1 therapies. Data from the OCTANE study found that people moving from Eli Lilly's LLY…
Merck MRK has entered into an exclusive global licensing agreement with SciBrunch Therapeutics, a China-based biotech company, for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor. Under the deal, Merck obtained exclus…
Acadia Pharmaceuticals ACAD has strengthened the intellectual property protection surrounding trofinetide, marketed in the United States as Daybue, following a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO). The allo…
Acadia Pharmaceuticals ACAD announced phase III-enabling top-line results from the phase II portion of the RADIANT study evaluating remlifanserin for the treatment of hallucinations and delusions associated with Alzheimer's disease psychos…
Immunovant IMVT announced top-line data from a proof-of-concept study that evaluated its lead and sole pipeline asset, IMVT-1402 (imeroprubart), a next-generation neonatal fragment crystallizable receptor (FcRn) inhibitor, for the treatmen…
Vertex Pharmaceuticals VRTX announced positive data from the phase IIb AMPLIFIED study, which evaluated its investigational drug, inaxaplin, for the treatment of patients with APOL1-mediated kidney disease ("AMKD") and modest proteinuria a…
AstraZeneca AZN announced that the European Commission has approved its respiratory drug, Trixeo Aerosphere, for a new indication. The drug is approved in the European Union (EU) as a maintenance treatment for previously treated asthma pat…
AbbVie ABBV announced that the European Commission ("EC") has approved its blockbuster immunology drug, Rinvoq (upadacitinib), for a new indication. The drug is approved in the European Union for the treatment of active polyarticular juven…
Novo NVO announced top-line results from two phase III studies evaluating once-weekly CagriSema, its investigational fixed-dose combination of cagrilintide and semaglutide, in obesity and type II diabetes (T2D). In the REIMAGINE 5 study, C…
AstraZeneca AZN announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending the approval of its rare-disease drug, Klygefa (gefurulimab), as an add-on…
Novo NVO announced that its once-weekly growth hormone therapy Sogroya (somapacitan) received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) for treating children with idiopath…
Novo NVO announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion recommending the approval of denecimig (Mim8) for the treatment of hemophilia A, with or witho…
Xenon Pharmaceuticals XENE announced that it has submitted a new drug application (NDA) to the FDA for azetukalner, its lead investigational therapy for the treatment of focal onset seizures (FOS) in epilepsy. If approved, the company will…
Shares of Ultragenyx Pharmaceutical RARE jumped 12.6% on Thursday after the FDA granted standard full approval to Fayuvi (rebisufligene etisparvovec-hopf), also known as UX111. The one-time gene therapy is approved for treating the neurolo…
Shares of Kiniksa Pharmaceuticals International KNSA have soared 41% over the past three months, driven by strong sales growth from its leading commercial product, Arcalyst, upward revisions to the company's 2026 revenue outlook and encour…
Novo NVO is expanding its artificial intelligence (AI) capabilities through a new collaboration with Anthropic to accelerate drug discovery and development of new medicines. Under the agreement, Novo will use Anthropic's models and Claude…
Gilead Sciences GILD has signed an agreement with the Pan American Health Organization (PAHO) to accelerate access to twice-yearly lenacapavir for HIV prevention across PAHO Member States in Latin America and the Caribbean. The agreement w…
GSK plc GSK has entered into an agreement to acquire an investigational trispecific T-cell engager (TCE) from Chimagen Biosciences, a privately held biotechnology company. Under the agreement, GSK will pay Chimagen an upfront payment in ex…
GSK plc GSK announced positive data from the registrational phase I/II ARROS-1 study evaluating its oncology drug, Jideytro (zidesamtinib), for the first-line treatment of patients with advanced or metastatic ROS1-positive non-small cell l…
AbbVie ABBV announced positive top-line data from the phase III LUNA study, which evaluated atogepant, an oral calcitonin gene-related peptide receptor antagonist, for preventive treatment of menstrual migraine in adult women. Menstrual mi…
Bayer BAYRY announced that the FDA has granted approval to sevabertinib through an accelerated pathway for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have…
Summit Therapeutics SMMT stock climbed 17.3% on Thursday after its Chinese partner Akeso reported positive overall survival (OS) results for ivonescimab in a head-to-head phase III study against Merck's MRK blockbuster oncology drug, Keytr…
Shares of Krystal Biotech KRYS have risen 13.4% over the past month compared with the industry's 8.2% growth, fueled by improving investor confidence in the company's commercial performance and its expanding pipeline of genetic medicines.Z…
United Therapeutics UTHR recently announced that the FDA has accepted its supplemental new drug application (sNDA) for review, seeking approval for expanded use of its marketed drug, nebulized Tyvaso, in idiopathic pulmonary fibrosis (IPF)…
Ultragenyx Pharmaceutical RARE stock is down 46% in premarket trading today after the company reported that the late-stage study evaluating its investigational antisense oligonucleotide candidate, apazunersen (GTX-102), for Angelman syndro…
AstraZeneca AZN announced positive data from the phase III SANOVO study evaluating Tagrisso (osimertinib) plus Orpathys (savolitinib) in treatment-naïve patients with EGFR-mutated advanced or metastatic non-small cell lung cancer (NSCLC) w…